CARM1 and plasma cell myeloma: This includes specific resistance to the proteasome inhibitor bortezomib in multiple myeloma, which is driven by an N6-methyladenosine (m6A)-mediated upregulation of lncRNA H19, functioning as a sponge to regulate the miR-184/CARM1 axis [67].